MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12967-026-08253-4

Медицинская библиотека · Journal of translational medicine · 2026

Metrnl in diabetes and its complications: divergent evidence and translational prospects.

Zhang Shengwei, Tang Jiayang, Liu Guiyu, Meng Biying, Hu Kang, Zhou Yongqiang, Yang Xiaoliang, Tang Qingyun, Liu Yuyang, Yue Ling

СтатьяОбзорПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Meteorin-like protein (Metrnl) is a novel secreted protein produced by multiple tissues, which is involved in metabolic regulation, immune homeostasis, and tissue repair. In recent years, research on the role of Metrnl in diabetes has advanced significantly. However, substantial controversies persist regarding its expression dynamics, protective roles, and underlying molecular mechanisms in diabetes and its complications.

MAIN BODY: This review synthesizes current evidence to systematically analyze the complex roles of Metrnl in diabetes. Preclinical studies have demonstrated that Metrnl primarily improves insulin resistance, protects pancreatic β-cells, and mitigates diabetes related damage to kidney, heart, and skin through multiple pathways, including the KIT receptor, AMPK and Wnt/β-catenin signaling pathways.In contrast, clinical data exhibit significant heterogeneity. Reports on circulating Metrnl levels in patients with type 2 diabetes are highly inconsistent, with findings of decreased, increased, or no significant changes. Such discrepancies are largely attributed to methodological inconsistencies and clinical confounders. Similar inconsistencies are observed in studies on gestational diabetes. Importantly, Metrnl also displays markedly different or even opposing expression patterns across various diabetic complications, highlighting its tissue-specific regulatory characteristics.

CONCLUSIONS

In summary, Metrnl is a pleiotropic molecule involved in the pathophysiological processes of diabetes and its complications, and it holds potential as a candidate biomarker or therapeutic target. However, its clinical translation faces key challenges, including insufficient standardization of detection methods, unclear characterization of receptor systems, and undefined pharmacological properties. Therefore, although Metrnl shows promise in preclinical models, its clinical utility requires rigorous validation, and its roles should be interpreted cautiously based on the current body of evidence.

Для цитирования: Zhang Shengwei, Tang Jiayang, Liu Guiyu, Meng Biying, Hu Kang, Zhou Yongqiang, Yang Xiaoliang, Tang Qingyun, Liu Yuyang, Yue Ling. Metrnl in diabetes and its complications: divergent evidence and translational prospects.. Journal of translational medicine. 2026. DOI: 10.1186/s12967-026-08253-4.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.